The domestic pharmaceutical industry bounced back to a nearly double-digit year-on-year growth in 2018 (9.4 per
cent), after falling to an eight-year low (5.5 per cent) in the previous year.
Read more: https://www.business-standard.com/article/companies/indian-pharma-industry-records-9-4-growth-in-2018-dispels-gst-gloom-119011000018_1.html
The company announced Wednesday it has authorized its subsidiary IJ Therapeutics to produce a largely identical
version of its automated naloxone injector for a retail price of $178 for a kit, which, like the $4,100 brand-name
version, contains two doses.
Read more : https://www.statnews.com/2018/12/12/kaleo-evzio-overdose-antidote-generic/
Vedanta’s experimental treatments are compositions of live bacteria that the Cambridge, MA, company says trigger a targeted immune response.
Read more : https://xconomy.com/boston/2018/12/24/gates-foundation-bristol-myers-join-27m-funding-for-vedanta-bio/
Indian pharma companies have been going through a tough phase for the past couple of years due to significant
competitive intensity and pricing pressure in the US (the largest market) and regulatory hurdles in India in terms
of demonetization, GST implementation and lower prices.
Read more at: http://economictimes.indiatimes.com/articleshow/67297361.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
The rapidly changing global pharmaceutical landscape reached another milestone Tuesday as Takeda Pharmaceutical
Co. completed its $62 billion acquisition of Shire Plc.
Read more : https://www.bloomberg.com/news/articles/2019-01-07/how-takeda-s-62-billion-shire-deal-reshapes-the-pharma-world